• SOPH

Earnings call: SOPHiA GENETICS reported a16% year-over-year increase in analysis volume

SOPHiA GENETICS Q3 2024 results show increased analysis volume, reduced cash burn, and strategic leadership changes, despite biopharma revenue decline, signaling a focus on growth and market stabilization.